Revelation Biosciences 3Q 2026: EPS ($5.92) — 10-Q Summary
Revelation Biosciences reported a wider net loss for 3Q 2026, with expenses rising due to increased R&D and administrative costs. The company has no revenue. GEM-AKI program and manufacturing costs drove much of the expense growth. Cash reserves were $9.1M, but not enough for a full year of operations. Diluted EPS was ($5.92).
How this was made

The 30-second read
Why it matters
The widened loss and limited cash runway suggest heightened execution risk, likely prompting a sell‑off in the stock.
Market read
Micro‑cap biotech earnings with cash‑burn concerns; limited impact beyond sector.
What to watch
Potential upcoming partnership or grant not disclosed in the filing could mitigate cash concerns.
Background
Revelation Biosciences Inc. (REVB) filed its Q3 2026 Form 10‑Q, reporting a net loss of $3.32 M and cash of $9.1 M, insufficient for a full year of operations.
Ticker impact
10-Q shows widened net loss and cash runway insufficient beyond one year, new quarterly financials.
likely downward pressure as market prices in the widening loss and cash concerns
Micro‑cap biotech with no revenue; fresh loss figures and cash runway raise execution risk.
Market effects
Highlights cash‑burn pressures in early‑stage biotech sector.
Minimal broader market effect; confined to niche biotech investors.
Low global relevance.
Counterpoint
If the company secures additional financing, the loss may be viewed as a temporary hurdle.
Key entities
- companyRevelation Biosciences Inc.
Micro‑cap biotech reporting Q3 2026 results.